Profiling antibody signature of schizophrenia by Escherichia coli proteome microarrays
Open Access
- 30 July 2022
- journal article
- research article
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 106, 11-20
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 108-2628-B-006-015, MOST 111-2321-B-006-008)
This publication has 61 references indexed in Scilit:
- Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood–brain barrier integrityMolecular Psychiatry, 2013
- Neurocognitive Outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders StudyJournal of the American Academy of Child & Adolescent Psychiatry, 2012
- Neurodevelopmental hypothesis of schizophreniaThe British Journal of Psychiatry, 2011
- Identification of Novel Serological Biomarkers for Inflammatory Bowel Disease Using Escherichia coli Proteome ChipMolecular & Cellular Proteomics, 2009
- Neuropsychological Profile in Early-Onset Schizophrenia-Spectrum Disorders: Measured With the MATRICS BatterySchizophrenia Bulletin, 2009
- Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodiesThe Lancet Neurology, 2008
- Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) StudyAmerican Journal of Psychiatry, 2008
- Applications of protein microarrays for biomarker discoveryProteomics – Clinical Applications, 2008
- A proteome chip approach reveals new DNA damage recognition activities in Escherichia coliNature Methods, 2007
- Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' seraGlia, 2003